Brind.

The FDA approved an automated platform for the T-SPOT test, and a partnership was established to enhance newborn genomic screening services.

1 report, 1 independent Updated Jul 24

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA RevvityGenomics England

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Revvity
American biotech company
- Revvity and Codexis, both healthcare companies, are currently competing against each other for market share.Sun 08:23
- Dovish remarks made on September 3, 2025, eased market concerns regarding high interest rates, involving the FED and Jerome Powell.Sun 01:44

Coverage

Newest first; wire copies grouped

Jul 24ZacksRevvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat? Revvity, Inc. RVTY is slated to report second-quarter 2025 results on July 28, before market open. In the last reported quarter, the